Search research articles
Contact Us
Filters
Showing results (61-70 of 86) with videos related to
Page
of 9
Sort By:
Cancers
|
July 2, 2021
Prognostic Association between Common Laboratory Tests and Overall Survival in Elderly Men with De Novo Metastatic Castration Sensitive Prostate Cancer: A Population-Based Study in Canada
Christopher J D Wallis, Bobby Shayegan, Scott C Morgan, et al.
European Urology Focus
|
November 5, 2021
Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers
Alice Dragomir, Sara Nazha, Simon Tanguay, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
October 29, 2024
Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer
Geoffrey T Gotto, Steven M Yip, Bobby Shayegan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 2022
Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA
Nobuaki Matsubara, Johann de Bono, David Olmos, et al.
The Lancet. Oncology
|
September 23, 2014
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial
Cora N Sternberg, Daniel Castellano, Gedske Daugaard, et al.
Urologic Oncology
|
February 26, 2022
Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in Canada
Bobby Shayegan, Christopher J D Wallis, Shawn Malone, et al.
Investigational New Drugs
|
May 7, 2013
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)
Suzanne Richter, Philippe L Bedard, Eric Xueyu Chen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 19, 2022
Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy
Jeffrey Graham, John Connor Wells, Shaan Dudani, et al.
Journal for Immunotherapy of Cancer
|
November 3, 2022
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy
Toni K Choueiri, Harriet Kluger, Saby George, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
February 8, 2022
Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction
Pei Jye Voon, Eric X Chen, Helen X Chen, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 86) with videos related to
Sort By:
Page
of 9
Cancers
|
July 2, 2021
Prognostic Association between Common Laboratory Tests and Overall Survival in Elderly Men with De Novo Metastatic Castration Sensitive Prostate Cancer: A Population-Based Study in Canada
Christopher J D Wallis, Bobby Shayegan, Scott C Morgan, et al.
European Urology Focus
|
November 5, 2021
Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers
Alice Dragomir, Sara Nazha, Simon Tanguay, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
October 29, 2024
Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer
Geoffrey T Gotto, Steven M Yip, Bobby Shayegan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 2022
Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA
Nobuaki Matsubara, Johann de Bono, David Olmos, et al.
The Lancet. Oncology
|
September 23, 2014
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial
Cora N Sternberg, Daniel Castellano, Gedske Daugaard, et al.
Urologic Oncology
|
February 26, 2022
Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in Canada
Bobby Shayegan, Christopher J D Wallis, Shawn Malone, et al.
Investigational New Drugs
|
May 7, 2013
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)
Suzanne Richter, Philippe L Bedard, Eric Xueyu Chen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 19, 2022
Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy
Jeffrey Graham, John Connor Wells, Shaan Dudani, et al.
Journal for Immunotherapy of Cancer
|
November 3, 2022
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy
Toni K Choueiri, Harriet Kluger, Saby George, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
February 8, 2022
Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction
Pei Jye Voon, Eric X Chen, Helen X Chen, et al.
Page
of 9